Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 69 | 36 | 11 |
| Samples | 55 | 35 | 11 |
| Peptides | 62 | 33 | 8 |
Function
AGT · Angiotensinogen
The protein encoded by this gene, pre-angiotensinogen or angiotensinogen precursor, is expressed in the liver and is cleaved by the enzyme renin in response to lowered blood pressure. The resulting product, angiotensin I, is then cleaved by angiotensin converting enzyme (ACE) to generate the physiologically active enzyme angiotensin II. The protein is involved in maintaining blood pressure, body fluid and electrolyte homeostasis, and in the pathogenesis of essential hypertension and preeclampsia. Mutations in this gene are associated with susceptibility to essential hypertension, and can cause renal tubular dysgenesis, a severe disorder of renal tubular development. Defects in this gene have also been associated with non-familial structural atrial fibrillation, and inflammatory bowel disease. [provided by RefSeq, Nov 2019].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000366667 | P01019 | 47 | 40 |
| ENST00000680783 | A0A7P0TAP4* | 12 | 12 |
| ENST00000679738 | P01019 | 7 | 7 |
| ENST00000681772 | A0A7P0T9S6* | 3 | 3 |
Gene Properties
Recurrent Mutations
All 40 amino-acid changes on canonical ENST00000366667 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in AGT · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in AGT – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 5/612 1% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Melanoma | 5/210 2% | 3/1899 0% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 1/1390 0% |
| Neuroendocrine Tumour | 2/154 1% | 0/577 0% |
| Cervical Carcinoma | 1/35 3% | 0/422 0% |
| Colorectal Carcinoma | 4/143 3% | 1/3239 0% |
| Hepatocellular Carcinoma | 1/46 2% | 2/2210 0% |
| Head and Neck Carcinoma | 1/85 1% | 1/1574 0% |
| Other Solid Cancers | 2/94 2% | 0/1515 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 0/810 0% |
| Gastric Carcinoma | 0/74 0% | 2/1809 0% |
| Non-Cancerous | 1/104 1% | 0/830 0% |
| Biliary Tract Carcinoma | 1/54 2% | 0/950 0% |
| Bladder Carcinoma | 0/58 0% | 1/956 0% |
| Ovarian Carcinoma | 1/109 1% | 0/998 0% |
| Breast Carcinoma | 0/144 0% | 3/3264 0% |
| Neuroblastoma | 1/87 1% | 0/1331 0% |
| Pancreatic Carcinoma | 1/89 1% | 0/1611 0% |
| Prostate Carcinoma | 1/13 8% | 0/2105 0% |
| Kidney Carcinoma | 0/85 0% | 1/1862 0% |
Mutation Distribution
Where AGT is mutated · all tissues, split by cell line vs tissue
How many mutations in AGT were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 69 mutations in AGT
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|